B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

BACKGROUND: PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients who have received B cell depleting drugs or with immunoglobulin deficiencies. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Damsky, William, Jilaveanu, Lucia, Turner, Noel, Perry, Curtis, Zito, Christopher, Tomayko, Mary, Leventhal, Jonathan, Herold, Kevan, Meffre, Eric, Bosenberg, Marcus, Kluger, Harriet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567557/
https://www.ncbi.nlm.nih.gov/pubmed/31200747
http://dx.doi.org/10.1186/s40425-019-0613-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567557/
https://www.ncbi.nlm.nih.gov/pubmed/31200747
http://dx.doi.org/10.1186/s40425-019-0613-1

Ejemplares similares